|
**Overview**: Chimerism Post-Engraftment Panel**Introduction**: The Chimerism Post-Engraftment Panel is a diagnostic tool designed to assess post-transplant chimerism using whole blood samples. In India, chimerism monitoring is critical after allogeneic HSCT to detect mixed chimerism, graft rejection, or relapse. High burden of hematological malignancies requiring HSCT, with post-engraftment analysis guiding intervention. High morbidity from under-monitoring in resource-limited centers leading to graft failure. Per hematology practices aligned with ICMR guidelines, the test employs PCR for donor/recipient DNA quantification over 1-2 days with high sensitivity/specificity, valuable for ongoing surveillance. This diagnostic falls under post-transplant evaluation and targets HSCT recipients, addressing accurate assessment to guide therapy. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise engraftment tracking. Its whole blood-based approach ensures reliable detection.**Other Names**: Chimerism Post Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology, compliant with 2025 standards.**Historical Milestone**: PCR-based chimerism standard; in India, essential in transplant follow-up.**Purpose**: The test assesses 2 parameters including donor DNA to guide post-engraftment chimerism, detect mixed status, inform management.**Test Parameters**: 1. Donor DNA, 2. Recipient DNA.**Pretest Condition**: No fasting required; patients should have post-HSCT monitoring need.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on transplant date, GVHD, relapse risk.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of mixed chimerism including relapse, benefits of monitoring, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High donor DNA indicates full engraftment; mixed/low indicates risk, necessitating specialist input.**Specialist Consultation**: Transplant hematologists should be consulted for management.**Additional Supporting Tests**: Lineage-specific chimerism for confirmation.**Test Limitations**: Whole blood only; comprehensive approach required.**References**: Indian Journal of Hematology 2024, HSCT Studies India 2023. |
